Access cutting-edge epidermolysis bullosa treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access epidermolysis bullosa specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related epidermolysis bullosa treatment provided free
INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.
Sponsor: Aegle Therapeutics
Check if you qualify for this epidermolysis bullosa clinical trial in Phoenix, AZ
If you're searching for epidermolysis bullosa treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced epidermolysis bullosa specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.